Lutetium-177 Market Lutetium-177 Market Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "Lutetium-177 Market by Form (Carrier ...

The median radiographic progression-free survival was 9.5 months with 177Lu-PNT2002 and 6.0 months with an androgen-receptor pathway inhibitor. 177 Lu-PNT2002 can improve progression-free survival ...

A new type of prostate cancer therapy that is used only in late-stage treatment where conventional therapy has failed has ...

A targeted radioactive infusion that is a game-changer in late-stage prostate cancer can also dramatically improve outcomes ...

ANSTO congratulated the Peter Macallum Cancer Centre led team, who recently reported the remarkable results of late-stage ...

Lu-177 dotatate is a molecular therapy. It is a type of peptide receptor radionuclide therapy (PRRT) used mainly for neuroendocrine tumors (NETs). PRRT combines a compound called a peptide with a ...

Rotorua cancer patient Daniel Hazelwood has spent $36,000 on private prostate cancer treatment this year. Without it, “I’d be ...

002). The combination of 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan; Pluvicto) with docetaxel improved outcomes in patients metastatic hormone-sensitive prostate cancer (mHSPC) without an ...

Not only does lutetium-177-PSMA-617 lower PSA levels in men with metastatic prostate cancer (mCRPC), PSA decline correlates with outcomes, research shows.

SN Nuclearelectrica SA and Framatome have announced the signing of a cooperation agreement to explore the possibility of producing the medical isotope Lutetium – 177 in the Cernavoda ...